TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28103611
Drug: Cabozantinib 100
Normalized name: cabozantinib 100 MG Daily Dose Carton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib 100 mg daily during a 12-week lead-in
Study: 22592176
Drug: Handled medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Handled medicine ball (HMB) throws included in the regular tennis practice
Study: 21757667
Drug: Intravenous tissue-type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tissue-type plasminogen activator (tPA) at a total dose of 0.9 mg/kg, with 10% given as a 1-minute bolus and the remainder over 1 hour
Study: 8508462
Drug: Sabeluzole 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sabeluzole 2 x 10 mg/d
Study: 8508462
Drug: Sabeluzole 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sabeluzole 3 x 10 mg/d
Study: 2832178
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus 600 cGy of both upper and lower half-body irradiation
Study: 21198719
Drug: Amikacin 15
Normalized name: amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amikacin 15 mg/kg once per day (group I)
Study: 21198719
Drug: Amikacin 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amikacin 7.5 mg/kg twice per day (group II)
Study: 17350868
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (fluticasone propionate 200 mcg/day by metered dose inhaler/spacer combination)
Study: 17350868
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (fluticasone propionate)
Study: 9351742
Drug: Nitric oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric oxide inhalation (30 ppm)
Study: 29071968
Drug: Regular medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular medication and swallowing function rehabilitation training
Study: 26645524
Drug: Ginger essence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger essence inhalation (2 drops on gauze, repeated every 30 min for 2 hours)
Study: 26645524
Drug: Ginger essence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger essence inhalation
Study: 21517667
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH), tinzaparin
Study: 18284511
Drug: 0.05% Clobetasol
Normalized name: CLOBETASOL PROPIONATE 0.5 mg in 1 g TOPICAL CREAM [Clobetasol Propionate Cream, 0.05% Clobetasol Propionate Cream, 0.05%]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% Clobetasol + 2.5% zinc sulphate cream
Study: 18284511
Drug: 0.05% Clobetasol
Normalized name: CLOBETASOL PROPIONATE 0.5 mg in 1 g TOPICAL CREAM [Clobetasol Propionate Cream, 0.05% Clobetasol Propionate Cream, 0.05%]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% Clobetasol alone cream
Study: 12728112
Drug: Naturopathic Herbal
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naturopathic Herbal Extract Ear Drops (NHED) 5 drops 3 times daily
Study: 12728112
Drug: Naturopathic Herbal
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naturopathic Herbal Extract Ear Drops (NHED) with topical anesthetic 5 drops 3 times daily
Study: 12728112
Drug: Topical anesthetic
Normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical anesthetic 5 drops 3 times daily
Study: 12728112
Drug: Oral amoxicillin
Normalized name: amoxicillin Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amoxicillin 80 mg/kg/d (maximum 500 mg/dose) divided into 3 doses with either NHED or topical anesthetic
Study: 12940661
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of recombinant tissue plasminogen activator (3 mg in 3 mL diluted into 250 mL of physiological saline solution, given every 12 hours)
Study: 10553534
Drug: Cilostazol 200
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cilostazol 200 mg/day for 3 months
Study: 10553534
Drug: Cilostazol 200
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cilostazol 200 mg/day for 6 months
Study: 29298077
Drug: Gabapentin only
Normalized name: Gabapentin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin only (900 mg/day)
Study: 29298077
Drug: Osteopathic Manipulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic Manipulative Medicine (OMM) only
Study: 29078965
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (standardized needle manipulation at LI10 and LI11 for 2 minutes)
Study: 26144850
Drug: ROM-6 (monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: ROM-6 (monthly rifampicin, ofloxacin, and minocycline for six months)
Study: 26144850
Drug: PB-MDT (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: PB-MDT (standard World Health Organization paucibacillary multidrug therapy)
Study: 21695893
Drug: Calcium 440
Normalized name: calcium carbonate 440 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium 440 mg/d and VD 100 IU/d
Study: 21695893
Drug: Calcium 440
Normalized name: calcium carbonate 440 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium 440 mg/d, VD 100 IU/d and soy isoflavone 100 mg/d
Study: 15333424
Drug: sivelestat (ONO-5046)
Normalized name: Sivelestat
DrugBank: Sivelestat (DB12863)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: sivelestat (ONO-5046) 0.2 mg/kg/h for 14 days
Study: 9287061
Drug: Modified Widman
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Widman flap and topical application of saturated citric acid at pH 1 for 3 minutes (CA group)
Study: 3446303
Drug: Time-limited therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time-limited therapy carried out by trainees
Study: 29354935
Drug: Auricular point
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular point sticking therapy combined with western medicine
Study: 29354935
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine only (control group)
Study: 25394430
Drug: Mannitol administration
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mannitol administration to kidney donors
Study: 23697857
Drug: Intravitreal diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal diclofenac (IVD) - 500 μg/0.1 mL
Study: 23697857
Drug: Intravitreal triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal triamcinolone (IVT) - 2 mg
Study: 17042147
Drug: Cetirizine hydrochloride
Normalized name: Cetirizine Hydrochloride
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetirizine hydrochloride (5 mg)‐pseudoephedrine hydrochloride (120 mg) (cetirizine‐D) twice daily
Study: 14572578
Drug: Etidronate (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etidronate (400 mg/day)
Study: 23756263
Drug: Transfusion to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfusion to raise haemoglobin to at least 10.0 g/dL
Study: 19875386
Drug: Gp IIb-IIIa
Normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gp IIb-IIIa inhibitors
Study: 16798772
Drug: Ropivacaine 2
Normalized name: fentanyl-ropivacaine 2 mcg/mL-0.1% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 2 mg h(‐1) (group R, n=22)
Study: 16798772
Drug: Ropivacaine 1
Normalized name: ROPivacaine 1% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 1 mg h(‐1) with morphine 8 microg h(‐1) (group RM, n=22)
Study: 16798772
Drug: Ropivacaine 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 7.5 mg ml(‐1) for continuous spinal anaesthesia
Study: 12783034
Drug: Ibuprofen (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (1200 mg x d-1)
Study: 12783034
Drug: Acetaminophen (4000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (4000 mg x d-1)
Study: 10839900
Drug: CIO (Continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIO (Continuous Insufflation of Oxygen) at a flow rate of 15 l/min
Study: 26847832
Drug: Active Hexose
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Hexose Correlated Compound (AHCC) 6.0 g for 2 months
Study: 26847832
Drug: Active Hexose
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Hexose Correlated Compound (AHCC)
Study: 22354671
Drug: TAP block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP block with 15 ml 0.25% bupivacaine (group T, n=25)
Study: 20113315
Drug: Cardi04-300 ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardi04-300 ml
Study: 20113315
Drug: Cardi04-150 ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardi04-150 ml
Study: 17030155
Drug: Placebo controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo controlled blood pressure lowering (ACE inhibitor-diuretic combination: perindopril-indapamide)
Study: 15853986
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with 3 or 5 MU IFN-alpha-2b thrice weekly and oral ribavirin (800-1200 mg/day) for 24 weeks
Study: 15853986
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with IFN-alpha and ribavirin
Study: 12030663
Drug: Combined warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined warfarin and aspirin, low doses
Study: 12030663
Drug: Warfarin alone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin alone, low doses
Study: 12030663
Drug: Aspirin alone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin alone, low doses
Study: 1907555
Drug: 1,25-dihydroxyvitamin D3
Normalized name: 1,25-dihydroxyvitamin D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,25-dihydroxyvitamin D3 ointment (1 microgram g-1) applied topically for 24 hours
Study: 1907555
Drug: 1,25-dihydroxyvitamin D3
Normalized name: 1,25-dihydroxyvitamin D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,25-dihydroxyvitamin D3 (10(-8) mol l-1) applied to cultured human keratinocytes for more than 9 days
Study: 31531421
Drug: Lignocaine liposomal
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine liposomal infusion only
Study: 31531421
Drug: Lignocaine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine plus epinephrine liposomal infusion
Study: 14972424
Drug: Aspirin +
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin + Warfarin (1.25mg of warfarin plus 75mg of aspirin)
Study: 14972424
Drug: Aspirin (75mg)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (75mg)
Study: 11502526
Drug: Clinafloxacin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinafloxacin (single oral doses)
Study: 9210065
Drug: All-trans retinoic
Normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All-trans retinoic acid (ATRA) with cytosine arabinoside (4 g/course, 1 to 9 courses every 4 weeks)
Study: 9210065
Drug: Cytosine arabinoside
Normalized name: Cytosine arabinoside
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytosine arabinoside (4 g/course, 1 to 9 courses every 4 weeks)
Study: 19660844
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g of casein
Study: 19660844
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g of whey protein
Study: 19660844
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g of whey protein combined with 5 g of essential amino acids
Study: 18498918
Drug: Inhibitron (test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhibitron (test formulation)
Study: 18498918
Drug: LosecA (reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: LosecA (reference formulation)
Study: 8763463
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg itraconazole daily for 12 weeks
Study: 28622082
Drug: Micro-needling combined
Normalized name: Salicylic Acid 0.002 TOPICAL PATCH [Egg micro needle soothing]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micro-needling combined with 10% TCA cream
Study: 24679046
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (40 IU) administered twice a day for 7.5 days
Study: 24679046
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered twice a day for 7.5 days
Study: 22223814
Drug: Drug company
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug company advertisements
Study: 17656469
Drug: DPC 333
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPC 333 at 5.5 mg/kg daily for 2 weeks in a rat collagen antibody-induced arthritis model
Study: 17656469
Drug: DPC 333
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPC 333 (oral)
Study: 17656469
Drug: DPC 333
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPC 333 (oral, single escalating doses)
Study: 11799030
Drug: Butterbur (carbon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butterbur (carbon dioxide extract tablets, ZE 339) one tablet, four times daily for two weeks
Study: 11799030
Drug: Cetirizine, one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine, one tablet in the evening for two weeks
Study: 7658296
Drug: Parents who
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parents who attended evening sessions of the drug prevention program
Study: 2096106
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg dimethindene maleate (Fenistil, Tropfen)
Study: 1015353
Drug: Postmyocardial Infarction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postmyocardial Infarction Clinic treatment
Study: 28926885
Drug: Intense pulsed
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense pulsed light (IPL) therapy with energy of 14-16 J/cm²
Study: 28926885
Drug: Control eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control eye receiving placebo therapy with 0 J/cm²
Study: 16807281
Drug: Oral HRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral HRT (conjugated equine estrogen 0.625 mg/day for 6 months)
Study: 16807281
Drug: Transdermal HRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal HRT (17beta‐estradiol gel 0.6 mg/day for 6 months)
Study: 12891248
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with fluvastatin (40 mg/day) and fenofibrate (200 mg/day)
Study: 1549214
Drug: Deprenyl (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deprenyl (10 mg/d)
Study: 26983055
Drug: Indirect moxibustion
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indirect moxibustion therapy
Study: 24565387
Drug: Intravenous clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous clonidine (2 μg/kg)
Study: 20435194
Drug: Tolvaptan (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan (oral vasopressin receptor antagonist)
Study: 11876714
Drug: Bifidobacterium animalis
Normalized name: Bifidobacterium Animalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacterium animalis DN-173 010 (three 125 g cups per day of fermented milk)
Study: 8525285
Drug: 400 micrograms/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 micrograms/kg with a clearing dose
Study: 8525285
Drug: 400 micrograms/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 micrograms/kg without a clearing dose
Study: 8525285
Drug: 600 micrograms/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 micrograms/kg with a clearing dose
Study: 8525285
Drug: 600 micrograms/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 micrograms/kg without a clearing dose
Study: 8525285
Drug: 800 micrograms/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 micrograms/kg with a clearing dose
Study: 8525285
Drug: 800 micrograms/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 micrograms/kg without a clearing dose
Study: 2145407
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment for elderly patients with grade III or IV retinopathy, congestive heart failure, or cerebral infarction or hemorrhage.
Study: 2145407
Drug: Non-pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-pharmacological treatment for elderly patients with established mild hypertension under 80 years of age.
Study: 2145407
Drug: Pharmacologic antihypertensive
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic antihypertensive treatment for elderly patients over 80 years of age or those with isolated systolic hypertension.
Study: 394868
Drug: CAMP chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAMP chemotherapy
Study: 394868
Drug: CCNU as
Normalized name: Lomustine
DrugBank: Lomustine (DB01206)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CCNU as a single agent
Study: 30734357
Drug: Intraluminal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraluminal therapy for H. pylori infection (ILTHPI)
Study: 22091267
Drug: Nasal beclomethasone
Normalized name: beclomethasone Nasal Spray
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal beclomethasone spray
Study: 22091267
Drug: Amoxicillin and
Normalized name: omeprazole, amoxicillin and rifabutin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin and decongestant (control group)
Study: 19782925
Drug: Daily walking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily walking distance measured by pedometer over one week
Study: 14687321
Drug: Comprehensive review
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive review and recommended modification of a patient's medication regimen
Study: 7965276
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (diuretic, beta-blocker or both)
Study: 31856942
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (standard NHS care for depression)
Study: 29307330
Drug: Inulin-type fructan
Normalized name: Inulin
DrugBank: Inulin (DB00638)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Inulin-type fructan prebiotic (Orafti® Synergy 1; 16 g/d)
Study: 29307330
Drug: Placebo (Glucidex®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Glucidex® 29 Premium; 16 g/d)
Study: 11792139
Drug: Eptifibatide (glycoprotein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eptifibatide (glycoprotein IIb/IIIa inhibitor)
Study: 10579750
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II antagonists at initial doses
Study: 10579750
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II antagonists at doubled doses
Study: 10579750
Drug: Hydrochlorothiazide 12.5
Normalized name: hydrochlorothiazide 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 12.5 mg daily added to initial doses of angiotensin II antagonists
Study: 2346518
Drug: Long-acting ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting ibuprofen (2,400 mg/day)
Study: 2346518
Drug: Flurbiprofen (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen (200 mg/day)
Study: 30794229
Drug: Outpatient physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient physical therapy (outpatient PT)
Study: 30794229
Drug: Time back
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Time back to activities of daily living, time off narcotics
Study: 28874304
Drug: Cricoid pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cricoid pressure with i-gel
Study: 28874304
Drug: Sham pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham pressure with i-gel
Study: 25630627
Drug: Atorvastatin dentifrice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin dentifrice (2% atorvastatin)
Study: 23982340
Drug: Tacrolimus QD
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus QD 0.2 mg/kg per day (Arm 2)
Study: 23982340
Drug: Tacrolimus BD
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus BD 0.2 mg/kg per day (Arm 1)
Study: 23982340
Drug: Tacrolimus QD
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus QD 0.3 mg/kg per day (Arm 3)
Study: 23982340
Drug: Tacrolimus QD
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus QD 0.2 mg/kg per day with mycophenolate mofetil, basiliximab, and corticosteroids (Arm 4)
Study: 20110160
Drug: Simvastatin plus
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin plus qualitative lifestyle (S+L)
Study: 20110160
Drug: Qualitative lifestyle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qualitative lifestyle advice (L)
Study: 17935515
Drug: Pimecrolimus cream
Normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pimecrolimus cream 1% and Vehicle cream (control)
Study: 11468422
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of SQV SGC twice daily + 100 mg of RTV twice daily (normal breakfast)
Study: 11468422
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of SQV HGC twice daily + 400 mg of RTV twice daily (normal breakfast)